Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 16/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20635326 | 0.79 | NLRP3 (0.42) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL25822346 | 0.76 | NLRP3 (0.41) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL22251836 | 0.75 | NLRP3 (0.39) | NLRP3ALDH1A1ATMSMN1; SMN2CA2 | |
| SCHEMBL22705177 | 0.72 | NLRP3 (0.30) | NLRP3 | |
| SCHEMBL21646719 | 0.71 | NLRP3 (0.42) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL19505705 | 0.71 | NLRP3 (0.46) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL23674580 | 0.71 | NLRP3 (0.42) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL26590829 | 0.70 | NLRP3 (0.45) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21963014 | 0.70 | ALDH1A1 (0.45) | NLRP3ALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL22705368 | 0.69 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571187-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH INC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3880666-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| WO-2023098612-A1 | SALT FORM AND CRYSTAL FORM OF DIMETHYL SULFOXIMINE DERIVATIVE | 南京明德新药研发有限公司 | 2023-06-08 | — | — | WO | disclosed |
| EP-3445756-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| EP-3445757-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RES INC (US) | 2020-11-25 | — | — | EP | disclosed |